Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
about
Challenges and future in vaccines, drug development, and immunomodulatory therapyBiomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severityStimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infectionDouble-stranded RNA-activated protein kinase regulates early innate immune responses during respiratory syncytial virus infectionControl of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease.The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity.Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infectionImmunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.Animal pneumoviruses: molecular genetics and pathogenesis.Viral load drives disease in humans experimentally infected with respiratory syncytial virusImmunoprophylaxis of respiratory syncytial virus: global experience.Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infectionThe G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.Major histocompatibility complex-dependent cytotoxic T lymphocyte repertoire and functional avidity contribute to strain-specific disease susceptibility after murine respiratory syncytial virus infectionPrenatal Exposure to Respiratory Syncytial Virus Alters Postnatal Immunity and Airway Smooth Muscle Contractility during Early-Life ReinfectionsThe interdependencies of viral load, the innate immune response, and clinical outcome in children presenting to the emergency department with respiratory syncytial virus-associated bronchiolitisProspects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.Universal vaccine against respiratory syncytial virus A and B subtypes.Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance PCharacterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.Respiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration.Human genetic factors and respiratory syncytial virus disease severity.IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation.STAT1 negatively regulates lung basophil IL-4 expression induced by respiratory syncytial virus infectionMucosal antibody responses are directed by viral burden in children with acute influenza infection.The host response and molecular pathogenesis associated with respiratory syncytial virus infection.Cell cycle arrest by transforming growth factor beta1 enhances replication of respiratory syncytial virus in lung epithelial cellsEnhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope proteinPGI2 as a regulator of CD4+ subset differentiation and function.Therapeutic approaches using host defence peptides to tackle herpes virus infections.Central nervous system alterations caused by infection with the human respiratory syncytial virus.Respiratory Syncytial Virus Infection Triggers Epithelial HMGB1 Release as a Damage-Associated Molecular Pattern Promoting a Monocytic Inflammatory Response.
P2860
Q26853354-4300152E-5411-441D-9F0A-46818D48A64EQ27010165-E608D55D-111B-4E9B-95C5-330C04781DEBQ27334724-8759F998-C2E6-49F0-BB37-CF28F28367FCQ28509475-FFF4E03C-53EB-4390-B430-16F22272432AQ30301182-476034B1-9BAF-467F-B6EC-4BDB4DBB3800Q30412460-3261A814-2FD6-43E5-8026-593404EA5250Q33558475-D2767940-E78E-4134-8422-BC716322244AQ33847030-083F9063-953A-46C7-8654-F0D8845AAA1DQ33930308-843F8D5E-9286-45AB-961E-15EFF9BA7355Q34120191-D2801353-0B70-42D6-AAA9-DFE1D5394D12Q34120278-95737C63-23EE-4E17-9648-31CA82797B64Q34186010-CBD94DB9-1F80-4D38-B160-BFF758211283Q34226850-A908F964-6680-470A-BF24-7A92C6518BFBQ34313560-B993F764-C9F0-4FC3-8587-7446C54AAC2EQ34402459-3FBED93E-DC3F-4990-9E43-0E72A26AFE1AQ34740842-16B5AAF4-5E80-4CE1-9D88-4A23882D1ED4Q34943083-07D3B96D-9263-41B0-B245-D061658E85FAQ34996665-5739271F-821D-4BDB-AD0A-A962B1679C8CQ35382696-1AE1E6A3-DEB4-4387-9065-0CD79F7A479FQ36274090-FF010BCD-3AD9-4922-A9E0-A20EDCBDDF01Q36299483-62201444-7470-4E9E-8FF0-2BD24F2752F4Q36322131-13C27529-6993-4BEB-9BC9-CE7FAE376B1EQ36338294-21ADBD7B-BC58-4345-9078-BFACD5626F8BQ36464353-0FD872B2-4A48-4100-A19C-A0147838A2A5Q36684360-8E6F5EFC-C8E6-481F-AB39-AD2F1735E62BQ36803900-543D6725-0FB1-4730-9FF7-9D85D7A6955FQ36810987-BFC2A3AC-3718-4D2C-AADE-6701BF72C5FEQ36935746-6D37069E-210D-4CC1-894A-884C9A6D15EAQ36943137-B9DF15EF-07B7-4137-9F97-861DF78C4996Q36955209-C1096020-B3E6-4665-B6DB-0ECB9043100FQ37110768-8D46E84E-FAC9-4392-AF47-92E3F0EA192FQ37127325-29942ED1-2A6E-4109-BBBA-F7600431EEBEQ37179280-17FC8C64-4E1B-4C31-BD24-5EC8A2B3FED9Q37263779-72D76731-3CDA-40F4-A0DF-A3545F5C9986Q37451996-B9ED042B-6A0D-41BF-8059-8A50BA3DAB22Q37511699-972C1879-7AD2-43FF-844B-7CB7093C558AQ37921880-050CE17F-3D56-4993-8F75-7C7F1A420E55Q37945181-ED647EAF-D8F1-4D6F-86AF-F02E09831B53Q38260281-037CE88C-5076-4C40-BCC7-590B26A65353Q38751350-8653F4F9-CEDF-43F1-ABA3-E3E068676139
P2860
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@ast
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@en
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@nl
type
label
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@ast
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@en
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@nl
prefLabel
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@ast
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@en
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@nl
P2093
P1433
P1476
Immune-mediated disease pathogenesis in respiratory syncytial virus infection.
@en
P2093
P304
P356
10.1016/S0162-3109(00)00233-2
P577
2000-07-01T00:00:00Z